Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARK: Cinpanemab in Early Parkinson's Disease
NCT03318523Phase 2Terminated
- Sponsor
- Biogen
- Start
- Jan 2018
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of cinpanemab in Parkinson's disease (PD), sponsored by Biogen. Started Jan 2018; status: terminated.
02
Drugs
cinpanemab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03318523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318523.